Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 86

Results For "NSE"

2392 News Found

Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024
Biotech | September 25, 2024

Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024

These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity


WHO endorses Roche’s dual-stain cytology testing in its cervical cancer prevention guidelines
Clinical Trials | September 23, 2024

WHO endorses Roche’s dual-stain cytology testing in its cervical cancer prevention guidelines

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results


Sightsavers India and AbbVie India host consultation on Glaucoma prevention in Bhopal
Healthcare | September 23, 2024

Sightsavers India and AbbVie India host consultation on Glaucoma prevention in Bhopal

The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up


Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
Drug Approval | September 23, 2024

Bavarian Nordic receives EMA approval of mpox vaccine for adolescents

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA


Pfizer and BioNTech receive positive CHMP opinion for Omicron KP.2-adapted COVID-19
News | September 23, 2024

Pfizer and BioNTech receive positive CHMP opinion for Omicron KP.2-adapted COVID-19

Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization


Fasenra recommended for approval in the EU by CHMP for treatment of EGPA
Drug Approval | September 23, 2024

Fasenra recommended for approval in the EU by CHMP for treatment of EGPA

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids


AstraZeneca Pharma India to launch Palivizumab (Synagis) in October 2024
News | September 20, 2024

AstraZeneca Pharma India to launch Palivizumab (Synagis) in October 2024

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease


Suven Pharmaceuticals names Vivek Sharma as Executive Chairman
People | September 20, 2024

Suven Pharmaceuticals names Vivek Sharma as Executive Chairman

Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform


Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant
News | September 18, 2024

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant

The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD


Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
News | September 18, 2024

Lupin inks licensing agreement with Takeda to commercialize Vonoprazan

Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India